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ABSTRACT. Objective: To evaluate efficacy and safety of
lanreotide autogel (ATG) 120 mg injections every 4-8 weeks
in somatostatin analogue-naïve patients with acromegaly.
Design: Open, non-comparative, phase III, multicenter clin-
ical study. Methods: Fifty-one patients (28 women, aged 19-
78 yr): 39 newly diagnosed (de novo) and 12 who had pre-
viously undergone unsuccessful surgery (post-op, 11 macro
and 1 micro) were studied. ATG 120 mg was initially given
every 8 weeks for 24 weeks and subsequently changed ac-
cording to GH levels: if ≤2.5 µg/l every 8 weeks (group A, 17
patients); if 2.5-5 µg/l every 6 weeks (group B, 15 patients);
and if >5 µg/l every 4 weeks (group C, 19 patients). Treat-
ment duration was 48-52 weeks. The primary objective was
to control GH and IGF-I levels (GH≤2.5 µg/l and IGF-I nor-
malized for age/gender). Secondary objectives were to as-
sess GH, IGF-I, and acid-labile subunit (ALS) decrease, im-
provement of clinical symptoms and quality of life (QoL). Re-
sults: GH levels normalized in 32 patients (63%), similarly in
de novo and post-op patients (72% vs 50%, p=0.48); in
100% of group A, in 73% of group B and in 21% of group C
(p<0.0001). IGF-I levels normalized in 19 patients (37%), sim-
ilarly in the de novo and post-op patients (33% vs 50%,
p=0.48): in 65% of group A, 33% of group B, and in 16% of
group C. Circulating GH levels decreased by 80±17%, IGF-
I levels by 44±27%, and ALS by 30±17%. Symptoms (hy-
perhidrosis (68.6%), swelling (68.6%), asthenia (58.8%),
spine arthralgia (54.9%), and paresthesias (52.9%) and QoL
(from 9.1±7.9 to 6.1±6.6) significantly improved (p<0.001).
No patient withdrew from the study because of adverse
events (AE). The most frequent AE was diarrhea (76.2% of
patients): at study end 16 mild and 1 moderate diarrhea
were recorded. Gallstones developed in 12% of patients.
Conclusion: ATG 120 mg in somatostatin-naïve patients with
acromegaly controls GH secretion in 63% and IGF-I secre-
tion in 37% during a 48-52 week period without any differ-
ence between de novo and post-op patients. The treatment
was associated with improvement in clinical symptoms and
QoL and with a good, safe profile.
(J. Endocrinol. Invest. 32: 202-209, 2009)
©2008, Editrice Kurtis
INTRODUCTION
First-line treatment of acromegaly with surgical ade-
nomectomy in patients with macroadenomas fails in
more than 50% of patients, as defined by increased
levels of GH and IGF-I and persistence of clinical symp-
toms (1, 2). The development of somatostatin ana-
logues has made it possible to normalize GH and IGF-
I levels and to improve clinical symptoms in most of
the patients unsuccessfully operated (3). In recent
years, independent studies have demonstrated bene-
ficial effects of depot somatostatin analogues admin-
istered to newly diagnosed patients with acromegaly
as first-line treatment (4).
Lanreotide is a synthetic octapeptide analogue of so-
matostatin, which binds preferentially to pituitary so-
matostatin receptors to inhibit GH secretion (5), there-
fore reducing IGF-I levels. Its efficacy in patients with ac-
tive acromegaly was demonstrated in several clinical
studies and a marketing authorization has been obtained
in 52 countries world-wide for a micro-particle formula-
tion. This first registered galenic form of lanreotide 30
mg enabled the release of the peptide over a period of
7 to 14 days after im administration. 
In order to further extend the duration of the release of
the active ingredient, a new formulation of lanreotide,
lanreotide Autogel (ATG) 60 mg, 90 mg and 120 mg was
developed. The ATG formulation consists of a solution
of lanreotide in water with no additional excipients.
In a pharmacokinetic (PK) study conducted in 24 volun-
teers, ATG exhibited linear pharmacokinetics for the 60
to 120 mg doses and provided a prolonged dosing in-
terval and good tolerability (6). Caron et al. (7) demon-
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strated that the micro-particle lanreotide and the ATG
have equal efficacy, and proposed equivalent doses of
the two formulations. Lucas et al. (8) have confirmed
these results in a large multicenter trial. Efficacy of ATG
was reported up to 3 yr from treatment (9). Other studies
have subsequently demonstrated that ATG was as ef-
fective as octreotide-long acting release (LAR) in patients
with acromegaly (10-12).
Since data on the efficacy of ATG in patients with
acromegaly are still limited (13), the current study was
designed to assess efficacy and safety profile of ATG120
mg administered every 4 to 8 weeks for 12 months in so-
matostatin analogue-naive patients.
MATERIALS AND METHODS
Study design
This is an open, non-comparative, phase III, multicenter clin-
ical study.
Objectives 
The primary objective was to evaluate the efficacy of the ATG
120 mg on control of GH and IGF-I excess in acromegaly ac-
cording to the currently accepted criteria (14). The secondary
objectives were to assess decrease of GH, IGF-I, and acid-labile
subunit (ALS) levels, improvement of clinical symptoms and QoL
and safety profile.
Inclusion criteria 
Patients aged ≥18 yr with active acromegaly [serum GH levels
above 5 µg/l and/or above 1 µg/l after oral glucose tolerance
test (OGTT) and abnormal IGF-I values], who signed the written
informed consent form. Patients should not have undergone pi-
tuitary surgery less than 3 months before selection, somatostatin
analogues (except for a pre-surgical treatment of less than 3
months) or radiotherapy.
Exclusion criteria
Patients who had undergone pituitary surgery less than 3 months
before selection or previously treated with radiotherapy or pre-
viously treated with a somatostatin analogue for longer than 3
months or previously treated with a dopamine agonist (for a pe-
riod >3 months and interrupted <6 months before selection) or
requiring such treatment during the study. Patients suffering
from active malignant disease, except basocellular carcinoma
of the skin or in situ carcinoma of the uterine cervix. Women at
risk of pregnancy during the study, not consenting to take ade-
quate precautions against pregnancy. Pregnant or breast-feed-
ing patients. Patients who had known hypersensitivity to any of
the test materials or related compounds. Patients receiving any
unlicensed drug within the previous 30 days or scheduled to re-
ceive any unlicensed drug other than ATG during the course of
the study. Patients with evidence of drug/alcohol abuse. Patients
unable or unwilling to fully comply with the protocol.
Determination of sample size
The determination of sample size was made using nQuery pro-
cedures and assuming a rate of patients with normalized GH
levels at study end of at least 20% (minimum acceptable re-
sponse rate) to 40% (minimum relevant clinical rate). With a type
I error =0.05 (1-sided) and 90% power, the sample size required
was of 54 patients.
Patients 
Twenty-four centers participated in the study coordinated by G.
Lombardi (University “Federico II”, Naples, Italy). The inclusion of
a minimum of 2 patients (at least 1 newly diagnosed) was required
at each center. The study was approved by the Ethics Committees
of all Centers. Patients gave their written informed consent prior to
entering the study. The study was performed according to the prin-
ciples defined by the declaration of Helsinki (1964) and subsequent
modifications and in compliance with Good Clinical Practice (GCP).
Of 64 patients screened, 1 was excluded since the adenoma
spontaneously melted between selection and baseline visit. He
never took the study drug and was excluded from the statistical
analysis. Of the remaining 63 patients, 4 dropped out before
week 16 and therefore were not assigned to any treatment sub-
group and 8 patients dropped out between week 16 and the fi-
nal visit; 1 of 8 withdrew his consent to take part in the study.
Thus, the study population consists of 51 patients, 28 women
and 23 men, aged 19-78 yr (median 50 yr). Fasting baseline GH
levels (mean of 5 samples of a diurnal profile) were 19.4±21.3
µg/l (median 10.3 µg/l) and IGF-I levels were 703.4±274.2 µg/l
(median 697 µg/l). IGF-I levels proved to be 2.5 times (median)
above the upper limit of normal range (ULN) according to age-
and sex-normative data. On magnetic resonance imaging (MRI),
30 patients had macroadenomas, 19 had microadenomas, and
2 had empty sella. Of the 51 patients, 39 were newly diagnosed
(de novo) and 12 had previously undergone unsuccessful surgery
(post-op, 11 macro and 1 micro). Table 1 shows the character-
istics of the 2 groups at study entry.
Safety population
The safety population, as defined by the protocol, consists of
patients who received at least 1 study drug dosing and includes
63 patients. 
Hormonal evaluation
GH levels were assessed as a mean value of 5 samples at 30-
min intervals (starting between 08:00 and 09:00 h) taken at each
visit before the injection of ATG. At inclusion (V0) and at final
visit, GH concentrations after OGTT were also determined (da-
ta not shown). IGF-I and ALS levels were assessed as a single
sample taken at each visit at the same time as the first GH sam-
ple. All hormonal parameters were assessed in a central labo-
ratory (D.i.S.E.M. – University of Genoa).
De novo Post-op p
No. 39 12
Women/Men 21/18 7/5 0.85
Macroadenomas 19 11 0.03
Microadenomas 18 1 0.03
Empty sella 2 0 0.03
Age (yr) 53±14 40±12 0.008
Baseline GH levels (µg/l) 17.8±20.0 24.8±25.3 0.28
Nadir GH levels (µg/l) 2.7±3.8 3.0±2.6 0.51
GH suppression (%) 79.5±17.6 80.8±15.5 1.0
Baseline IGF-I levels (µg/l) 736.9±273.4 678.3±309.7 0.65
Nadir IGF-I levels (µg/l) 360.5±164.8 438.5±259.3 0.54
IGF-I suppression (%) 47.8±26.7 32.7±26.1 0.053
p-values for continuous variables were calculated with the Mann-Whit-
ney test. p-values for categorical variables were calculated with the Chi-
square test.
Table 1 - Patients’ profile at study entry. Patients are classified as
newly diagnosed (de novo) or as having already undergone un-
successful surgery (post-op).
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Study protocol
ATG120 mg was given as a deep sc injection into the buttock.
Once all baseline assessments had been performed, each pa-
tient received one deep sc injection of ATG 120 mg at Visit 1
(V1) and then a subsequent injection every 8 weeks for a total of
3 injections (period 1). Then, on the basis of GH levels (mean of
5 samplings at 30-min intervals) as measured at V3, the dosing
interval was determined as follows (period 2): if GH levels were
≤2.5 µg/l ATG 120 mg was maintained every 8 weeks for an-
other 3 injections (group A); if GH levels were between 2.5-5
µg/l, ATG 120 mg was given every 6 weeks for another 4 injec-
tions (group B); if GH levels were >5 µg/l, ATG 120 mg was giv-
en every 4 weeks for another 7 injections (group C). The duration
of treatment was 48-52 weeks. In this study we report the re-
sults obtained before starting ATG treatment and the lowest GH
and IGF-I level (nadir) measured after ATG treatment (Fig. 1).
Criteria for evaluation
Efficacy
We considered controlled the patients achieving GH levels as
mean of 5 samples in a diurnal profile ≤2.5 µg/l in the presence
of IGF-I levels normalized for age and gender. Improvement in
clinical symptoms was considered on the basis of a semiquanti-
tative scale for asthenia, hyperhidrosis, headache, swelling of
extremities, arthralgia, paresthesia, carpal tunnel syndrome:
symptoms were graded as 0= absent, 1= mild, 2= moderate,
3= severe. The Nottingham questionnaire was used at visit 1
and at the final visit of the study it was used to measure quality
of life (QoL).
Safety
Any adverse event (AE) during the study was monitored and re-
ported by the investigators. Safety, evaluated by local laborato-
ry data, was assessed at inclusion and at the final visit by: hema-
tology: erythrocytes, leukocytes, platelets, hemoglobin, hemat-
ocrit; biochemistry: glucose, creatinine, alkaline phosphatase, to-
tal bilirubin, alanine aminotransferase (ALT), aspartate amino-
transferase (AST), electrolytes (sodium, potassium, calcium, phos-
phorous), glycosylated hemoglobin, triglycerides, total and HDL
cholesterol, blood amylase, sideremia, transferrin, prothrombin;
glucose and insulin concentrations after OGTT; hormonal evalu-
ation: TSH, free T3 (FT3), free T4 (FT4), FSH, and LH levels. Safe-
ty related to gallbladder was assessed by ultrasound examina-
tion performed at inclusion and at the end of the study.
Methods
Serum samples for GH, IGF-I, and ALS measurements were col-
lected in fasting conditions and stored at –20 C until shipping to
the central lab. GH was measured by a chemiluminescent im-
munoradiometric assay (Immulite, DPC, Los Angeles, CA, USA).
The analytical sensitivity of this assay was 0.01 µg/l, standard
curve was calibrated against WHO 1st IRP 80/505 (1 mg=2.6
IU). IGF-I was measured by radioimmunoassay using immuno-
chemicals and tracer provided by Biosource (Nivelles, Belgium).
The assay sensitivity was 150 pg/ml (1.2 nmol/l). To avoid inter-
ference from binding proteins, single plasma EDTA were treat-
ed with acid ethanol. The values were compared with an ap-
propriate age-adjusted range as follows (3rd-97th percentile): 20-
29 yr: 76-389; 30-39: 60-353; 40-49: 68-266; 50-59: 62-252; 60-
65: 40-217.5; 66-75: 40-209 µg/l.
Total ALS was measured by specific two-site sandwich enzyme-
linked immuno-sorbent assay, using anti-ALS antibodies raised
against synthetic amino-terminal and carboxyl-terminal ALS pep-
tides, and reagents and tracer provided by Diagnostics Systems
Laboratories, Inc. (Webster, TX). All samples were pretreated to
dissociate the complexed ALS and enhance ALS immuno-reac-
tivity. The sensitivity of the assay was 4.7 nmol/l; the intra- and
inter-assay coefficients of variation were 5.5% and 7.2%, re-
spectively. Recovery of human serum-derived glycosilated ALS,
purified as previously described (15), was 75% for the lower con-
centration added (1 µg) and 95% for the higher concentration
added (60 µg). The values were compared with an appropriate
age-adjusted range (3rd-97th percentile) obtained by the same
laboratory in a large group of healthy subjects as follows: 20-29
yr =19.4-29.8, 30-39 yr =19.6-29.9, 40-49 yr =18.3-29.7, 50-59
yr =18.3-28.0, >65 yr 18.3-25.5 µg/l.
All hematological and biochemical tests, including thyroid func-
tion, glucose and insulin, were locally measured by routine assays.
Statistical methods 
The primary efficacy analysis was based on the per protocol pop-
ulation (51 patients). The assessment of safety was based on the
safety population (63 patients). The primary efficacy analysis as-
sessed the percentage and its 95% confidence interval (CI) of
patients with normalized GH levels, considered as mean GH val-
ue of 5 samples over 2 hours ≤2.5 µg/l. Comparison between
de novo and post-op patients was performed by the Mann-Whit-
ney test. Comparison among treatments groups A, B, and C was
performed by the Kruskal-Wallis test followed by the Dunn’s
24 weeks 24 weeks
ATG 120 mg every 8 weeks
screening
GH >2.5-≤5 µg/l
every 6 weeks
(Group B no.=15)
GH ≤2.5 µg/l
every 8 weeks
(Group A no.=17)
GH >5 µg/l
every 4 weeks
(Group C no.=19)
24 weeks
28 weeks Fig. 1 - Summary of the study protocol.
ATG: lanreotide autogel. 
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multiple comparison test. Differences in clinical symptoms were
analyzed by the Mc Nemar test. A two-side p-value <5% was
taken as statistically significant. Safety data were summarized
by descriptive statistics before and after ATG treatment. No in-
ferential statistical tests were performed. 
RESULTS
Post-op patients were significantly younger and had a
higher prevalence of macroadenomas than the de novo
ones (Table 1). The patients enrolled in groups A and B
were older and had lower GH (only group A) and IGF-I
levels at baseline than those of group C (Table 2).
Primary objective
Nadir GH levels normalized in 32 out of 51 (63%) patients
similarly in de novo and in post-op patients [26/39 (72%)
vs 6/12 (50%), p=0.48] and in females and in males [17/28
(61%) vs 15/23 (65%), p=0.97]. GH levels normalized in all
17 patients of group A (100%), 11 of 15 patients of group
B (73%) and in 4 of 19 patients of group C (21%;
p<0.0001). IGF-I levels normalized in 19 out of 51 (37%)
patients, similarly in de novo and post-op patients [13/39
(33%) and 6/12 (50%); p=0.48]. IGF-I levels normalized
in 11 of 17 patients of group A (65%), 5 of 15 patients of
group B (33%) and in 3 of 19 patients of group C (16%).
Of the 19 patients with normalized IGF-I levels only 1 had
unsuppressed GH levels (a 26-yr-old woman with a post-
op macroadenoma and a nadir GH of 5 µg/l). Of the re-
maining 14 patients with normalized GH levels, 4 (28%)
had near-normal IGF-I levels (1.01-1.3 times above the
upper limit of normal range). 
Secondary objectives
Serum GH and IGF-I levels
Mean GH level decreased from 19.4±21.3 µg/l at study
entry, to 7.0±6.8 µg/l at week 8 and 4.5±4.9 µg/l at the
final visit (p<0.0001). Percentage of GH suppression was
80±17%. Figure 2 shows the individual GH levels before
and after treatment, according to the different treatment
schedules (group A, B, and C). Similarly, mean IGF-I lev-
el decreased from 703.4±274.2 µg/l at study entry, to
526±264 µg/l at week 8 and 455.4±227.9 µg/l at the fi-
nal visit (p<0.0001). Percentage of IGF-I suppression was
44±27%. Figure 3 shows the individual IGF-I levels be-
fore and after treatment, according to the different treat-
ment schedules (group A, B, and C). Nadir GH and IGF-
I levels during ATG treatment in the patients enrolled in
groups A and B were significantly lower than those ob-
served in the patients of group C (Table 2).
ALS levels
The greatest decrease of ALS was also noticed on the first
visit after the treatment start, from 55.6±19.4 µg/ml at
week 0, to 45.1±18.9 µg/ml at week 8. At the final visit
the ALS level was 38.8±15.8 µg/ml (p<0.001). Percent ALS
suppression was 30±17%. ALS was significantly higher in
the patients of group C than in those of group A, in ac-
cordance with the results of IGF-I levels (Table 2). At treat-
ment end, ALS levels were decreased in all treatment
groups: in patients of group A and B ALS levels were sig-
nificantly lower than in patients of group C (Table 2).
Symptoms of acromegaly
The prevalence of symptoms at baseline and final visits is
summarized in Table 3. The most frequent symptoms at
baseline were hyperhidrosis (68.6%), swelling sensation
(68.6%), asthenia (58.8%), arthralgia of the spine (54.9%),
and paresthesias (52.9%). Those symptoms disappeared
in most patients after treatment (Table 3). The Mc Ne-
mar test confirmed a significant decrease of all symptoms
but two, namely arthralgia of the shoulder and arthralgia
of the pelvis, which affected a small number of patients. 
Quality of life: Nottingham Questionnaire
The QoL score, calculated as the sum of the disturbances
by the Nottingham Questionnaire, was 9.1±7.9 at the
first visit and decreased to 6.1±6.6 at the final visit. The
changes in single individuals at the end were –2 in me-
dian (–2.8±4.6) and were statistically significant at the
Wilcoxon Signed Ranks test (p<0.001) (Table 4).
Safety
In the safety population the average treatment duration
was 266.5±75.5 days (median 282 days). No patient with-
drew from the study because of AE. Three serious AE
were reported in 2 patients during the study: a male of
60 yr experienced diarrhea, considered to be probably
Group A Group B Group C p
No. 17 15 19
Women/Men 10/7 8/7 10/9 0.92
De novo/Post-op 13/4 12/3 14/5 0.86
Age (yr) 59±12a 52±13b 39±11 0.0003
Baseline GH levels (µg/l) 9.2±12.6a 16.9±19.0 30.5±24.7 <0.001
Nadir GH levels (µg/l) 0.8±0.4a 1.9±1.2b 5.1±4.1 <0.001
GH suppression (%) 84.5±10.5 78.7±17.3 76.6±20.9 0.57
Baseline IGF-I levels (µg/l) 594±279a 635±178b 855±275 0.0021
Nadir IGF-I levels (µg/l) 255±123a 347±140b 515±195 <0.001
IGF-I suppression (%) 53.3±25.8 39.5±33.4 39.9±21.3 0.15
Baseline ALS levels (µg/l) 45.6±15.0a 57.2±17.9 63.5±20.6 0.017
Nadir ALS levels (µg/l) 31.8±13.5a 35.7±12.3b 47.5±16.8 0.006
p-values for continuous variables were calculated with the Kruskal-Wallis test followed by Dunn’s multiple comparison test. p-values for categorical vari-
ables were calculated with the Chi-square test. ap<0.01 vs C; bp<0.05 vs C. Patients are classified as newly diagnosed (de novo) or as having already un-
dergone unsuccessful surgery (post-op). ALS: acid-labile subunit. 
Table 2 - Characteristics of the patients enrolled in group A (lanreotide-autogel 120 mg injections every 8 weeks), group B (lanreotide-
autogel 120 mg injections every 6 weeks) and group C (lanreotide-autogel 120 mg injections every 4 weeks). 
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related to study treatment and dyspnea due to atrial fib-
rillation and judged as unrelated to treatment; a woman
of 65 yr was admitted to hospital due to hypercortisoluria
classified as unrelated to treatment. Overall, during the
trial 60 out of the 63 patients complained of AE. The most
frequent AE was diarrhea, reported by 48/63 patients
(76.2%). At the final visit 16 mild and 1 moderate diarrhea
were recorded in 33.3% of patients. Pain and induration at
the injection site were reported in 27 patients (42.9%) and
abdominal pain was reported by 36 patients (57.1%). Nau-
sea was not frequent and mostly mild to moderate; se-
vere nausea was reported by 1 patient. Vomiting was rare,
severe in 1 patient. Abdominal cramps were less frequent
during the early treatment phase (Table 5).
Data on gallbladder ultrasonography both at baseline
and at the final visit were available in 50 patients. Out of
these, 2 patients (4%) had gallstones from the beginning
to the end of the study, and 6 (12%) developed gall-
stones during the study period (Table 5).
DISCUSSION
The results of the present study demonstrate that ATG
120 mg treatment at different intervals between injections
normalized GH and IGF-I levels in 63% and 37% of so-
matostatin-naive patients with active acromegaly, re-
spectively. No difference was found in the outcome of
ATG 120 mg in de novo and post-op patients, thus con-
firming previous results (16-19). A delayed interval be-
tween injections as long as 56 days was successful in 17 of
51 patients (33.3%) while in 19 patients (37.2%) the inter-
val was shortened to 28 days, which is similar to that com-
monly used in patients treated with octreotide-LAR. In-
termediate intervals between injections of 42 days was
used in the remaining 15 patients (29.4%). As expected,
shortening the interval between injections (that corre-
sponds to an increase in the final ATG dosage) was fol-
lowed by a lower success rate in terms of GH and IGF-I
normalization, indicating that the patients treated in this
study with ATG 120 mg every 28 days are less responsive
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Fig. 2 - Individual results of serum GH levels before and after
treatment with lanreotide autogel 120 mg every 56 days (A), ev-
ery 42 days (B) or every 28 days (C). The grey area corresponds
to the normal GH levels (≤2.5 µg/l).
Fig. 3 - Individual results of serum IGF-I levels before and after
treatment with lanreotide autogel 120 mg every 56 days (A), every
42 days (B) or every 28 days (C). The grey area corresponds to the
normal IGF-I levels for age, as reported in the Methods section. 
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to the treatment (20). A similar finding has already been
documented in patients treated with octreotide-LAR at
dosages of 30 to 40 mg every 28 days (17). ATG 120 mg
treatment was associated with significant improvement of
clinical symptoms and QoL and was found to have a safe-
ty profile similar to other somatostatin analogues. 
Up to now, no studies have reported the efficacy of ATG
treatment in newly diagnosed or in somatostatin ana-
logue-naive patients with acromegaly. Caron et al. (7, 9)
previously reported that the ATG formulation had an ef-
ficacy similar to that observed with the old lanreotide
slow release (SR) formulation as confirmed by Lucas et
al. (8). Dose equivalence was also proposed as ATG 60
mg, 90 mg, and 120 mg every 28 days are equivalent to
lanreotide SR 30 mg every 14 days, 10 days and 7 days,
respectively. Subsequent studies reported that the ATG
formulation had similar efficacy to octreotide-LAR (10-
12). Overall, 55 patients were reported after both LAR
and ATG at different dosages and after a wash out peri-
od: all three studies demonstrated that GH and IGF-I lev-
els were similar with either drug (10-12).
In the current study, we investigated for the first time a
large population of 51 patients who had never previously
received treatment with somatostatin analogues. The ma-
jority of the patients enrolled in the study were newly di-
agnosed (76.5%) while only a minority were enrolled after
unsuccessful surgery (23.5%). Normalization of GH and
IGF-I secretion did not differ in the 2 patient groups, in
line with previous findings (16-19). It is worth noting that
ATG 120 mg was successful in two thirds of the patients
even when injected with a 42-to 56-day interval between
injection. Indeed, control of GH excess was achieved in
100% and 73%, respectively, and age-normalization of
IGF-I levels in 65% and 33%, respectively, in patients treat-
ed every 56 and 42 days for 48 weeks. The prolonged in-
terval between injections may improve the patients’ com-
pliance to the long-term treatment: this issue was, how-
ever, not evaluated in detail in the current study. The out-
come of ATG 120 mg given every 28 days could be con-
sidered disappointing since only 21% and 16% of 19 pa-
tients achieved control of GH and IGF-I levels, respective-
ly. It should be considered, however, that shortening of
the interval between injections was allowed for the sec-
ond part of the study and was thus limited to 24 weeks
only. Therefore, the possibility that prolonged treatment
with a 28-day interval could induce further benefit in terms
of GH and IGF-I levels cannot be ruled out from the current
study. On the other hand, Cozzi et al. (21) have demon-
strated that prolonged treatment with octreotide-LAR in-
Baseline visit Final visit Delta p
No. (%) No. (%) (%)
Hyperhidrosis 35 68.6 14 27.5 –41.2% <0.001
Swelling sensation 35 68.6 14 27.5 –41.2% <0.001
Asthenia 30 58.8 19 37.3 –21.6% 0.008
Arthralgia of the spine 28 54.9 16 31.4 –23.5% 0.001
Paresthesias 27 52.9 10 19.6 –33.3% <0.001
Arthralgia of the extremities 22 43.1 10 19.6 –23.5% 0.001
Headache 21 41.2 11 21.6 –19.6% 0.007
Arthralgia of the knees 19 37.3 10 19.6 –17.6% 0.003
Arthralgia of the shoulder 13 25.5 7 13.7 –11.8% 0.053
Arthralgia of the pelvis 10 19.6 7 13.7 –5.9% 0.257
Carpal tunnel syndrome 10 19.6 3 5.9 –13.7% 0.008
p-values refer to the Mc Nemar Test results.
Group A Group B Group C p Total
No. 17 15 19 51
Baseline 11.1±8.1 10.0±9.8 6.7±5.5 0.22 9.1±7.9
Post-treatment 7.1±6.3 6.6±8.0 4.9±5.8 0.87 6.1±6.6
p <0.001
p-values refer to the Wilcoxon Signed Ranks test.
Patients
No. %
Not infective enteritis and colitis (diarrhea) 48 76.2
Abdominal pain 36 57.1
Pain or induration at the injection site 27 42.9
Arthropathy due to 24 38.1
endocrine/nutritional/metabolic diseases
Headache 20 31.7
Nausea and vomiting 16 25.4
Malaise and asthenia 11 17.5
Flatulence and related conditions 9 14.3
Cutaneous paresthesia 9 14.3
Gallbladder stone without cholecystitis 8 12.7
Abdominal pain, upper 6 9.5
Hyperhidrosis 6 9.5
Fever 5 7.9
Pruritus 4 6.3
Alopecia without skin scars 3 4.8
Constipation 3 4.8
Periapical dental abscess without fistula 3    4.8
Renal colic 3 4.8
Table 3 - Rate of patients with symptoms of acromegaly.
Table 4 - Descriptive statistics for Nottingham Questionnaire.
Table 5 - International classification of diseases,10th revision
(ICD10 classification), of adverse events.
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duced a progressive control of GH and IGF-I during a 9-yr
follow-up. Based on the similarities between octreotide-
LAR and ATG (10-12) which have been recently reviewed
by Murray and Melmed (22), long-term treatment with ATG
could be followed by progressive control of GH and IGF-
I levels and further studies are required to confirm this hy-
pothesis.
In the current study, we also investigated the change in
ALS levels after ATG 120 mg treatment. It has been sug-
gested that ALS, the main component of the circulating
150k-Da complex might be a good marker to reflect in-
tegrated GH secretion. Previous studies demonstrated
that ALS levels are reduced to normal levels after suc-
cessful surgery and radiotherapy (23-25). A recent study
failed to reveal normalization of ALS levels during ATG
120 mg treatment (26). It should be noted, however, that
Ronchi et al. did investigate patients already treated with
octreotide-LAR and that changes in ALS levels might al-
so depend on direct effects of somatostatin analogues
(26). We found that ALS levels nicely followed GH and
IGF-I reduction in the 51 patients: in fact, in patients of
group A and B, who had a greater response in terms of
GH and IGF-I than those of group C, ALS levels were sig-
nificantly lowered by ATG treatment.
The analysis of the clinical symptoms and of the ques-
tionnaire on the QoL also supported the results of GH
and IGF-I measurements. In fact, most of the clinical
symptoms, with the sole exception of arthralgias of pelvis
and shoulder, improved significantly in this cohort. At the
time of the study, a specific questionnaire to assess QoL
in acromegaly was not available as it currently is (27).
Nevertheless, a significant improvement in the Notting-
ham questionnaire was found in all patients. Even when
grouped according with the different treatment sched-
ules, a significant improvement of QoL remains and no
difference was found among groups. These data are par-
ticularly useful in consideration of the many systemic
complications that characterize acromegaly (28).
Lastly, ATG 120 mg was tolerated well by the patients
and none of the 63 patients enrolled in the study with-
drew from treatment because of side effects. The safety
profile was very similar to the well-known profile of so-
matostatin analogues, with gastrointestinal disturbances
being the most frequent complaints (3). Generally, how-
ever, disturbances subside spontaneously with treatment
continuation. New gallstones were documented in 12%. 
CONCLUSION
Lanreotide autogel 120 mg given to somatostatin-naïve pa-
tients with acromegaly at different injection intervals of 28,
42 or 56 days induce control of GH secretion in 63% and of
IGF-I secretion in 37% during a 48-52 week treatment pe-
riod. No difference in treatment outcome was observed
between newly diagnosed and post-surgery patients. The
treatment was also associated with improvement in clinical
symptoms and QoL with a good safe profile. These data,
together with the new findings demonstrating significant
tumor shrinkage of GH-secreting adenomas in newly diag-
nosed patients treated with lanreotide-Autogel (29), rein-
force the use of somatostatin analogues as first-line treat-
ment of acromegaly, as recently suggested (30).
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